Divi's Laboratories Limited (NSE:DIVISLAB)
India · Delayed Price · Currency is INR | Market Cap | 2.55T +59.0% |
| Revenue (ttm) | 112.30B +16.3% |
| Net Income | 29.25B +26.8% |
| EPS | 110.21 +26.9% |
| Shares Out | 265.47M |
| PE Ratio | 87.28 |
| Forward PE | 80.19 |
| Dividend | 30.00 (0.31%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 388,854 |
| Open | 9,602.00 |
| Previous Close | 9,602.00 |
| Day's Range | 9,530.00 - 9,668.50 |
| 52-Week Range | 5,636.50 - 9,740.00 |
| Beta | 0.24 |
| Analysts | Hold |
| Price Target | 8,447.00 (-11.71%) |
| Est. Earnings | Nov 4, 2026 |
About Divi's Laboratories
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. T... [Read more]
Financial Performance
In fiscal year 2026, Divi's Laboratories's revenue was 105.60 billion, an increase of 12.82% compared to the previous year's 93.60 billion. Earnings were 25.68 billion, an increase of 17.21%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for DIVISLAB stock is "Hold." The 12-month stock price target is ₹8,447, which is a decrease of -11.71% from the latest price.
News
Divi's Laboratories Transcript: Q1 26/27
Q1 FY 2027 delivered strong revenue and profit growth, led by custom synthesis and resilient generics, despite ongoing supply chain and cost challenges. Strategic inventory management, CapEx progress, and expansion in peptides and nutraceuticals supported performance.
Divi's Laboratories Quarterly report: Q1 2027
Divi's Laboratories has published its Q1 2027 quarterly earnings report on August 1, 2026.
Top stocks to buy today: Stock market recommendations for July 14, 2026 - check list
Stock market recommendations: Divi's Laboratories, Bajaj Finserv, Bharat Forge, and Coforge are the top stocks to buy recommended by Somil Mehta, Head of Retail Research at Mirae Asset Sharekhan for J...
39 Telangana cos among top 500 most valuable private sector companies in India
Hyderabad: As many as 39 companies from Telangana have made it to the list of top 500 most valuable companies in India, led by Divi's Laboratories wit.
Divi's Laboratories announces ₹30 per share dividend for FY 2025-26
Divi's Laboratories has announced a proposed dividend of ₹30 per fully paid-up equity share for the financial year ending March 31, 2026. This substantial dividend, representing a 1,500% return on…
Pharma sector stocks today, June 9: Panacea Biotech surges 9.11%, Divis Laboratories up 3.46%, Ajanta Pharma gains 1.86%
Pharma stocks traded largely in positive territory on June 9, 2026, during the morning session, with most stocks posting gains. The broader market was stable, with the Nifty 50 up…
Dividend stocks in focus: Axis Bank, Divi's Laboratories, Atul, D-Link India and others announce record dates
Several listed companies have announced dividend payouts along with their record and ex-dividend dates. Investors looking to qualify for these dividends will need to hold shares before the respective ...
Top stocks for trade today, June 8: ONGC, Divi's Laboratories, Zee Entertainment, Amber Enterprises, TVS Motor, Hindustan Zinc and more
Indian equity markets are expected to track company-specific developments on Monday, June 8, 2026. Several listed companies have announced business updates, project wins, acquisitions, partnerships, a...
Top stocks for trade today, May 25: Hindalco Industries, Torrent Pharma, Divi’s Lab, Eicher Motors, NTPC Green and more
Indian equity markets are likely to track several earnings-driven and corporate-specific developments on May 25. Companies including Hindalco Industries, Torrent Pharmaceuticals, Divi's Laboratories, ...
Divi's Laboratories Transcript: Q4 25/26
Q4 and FY26 saw strong revenue and profit growth, stable generics volumes, and robust custom synthesis and peptide pipelines. Despite global supply chain disruptions and rising costs, production and supply reliability were maintained, with a double-digit revenue growth outlook for FY27.
Divi's Laboratories Quarterly report: Q4 2026
Divi's Laboratories has published its Q4 2026 quarterly earnings report on May 23, 2026.
Divi's Laboratories Annual report: Q4 2026
Divi's Laboratories has published its Q4 2026 annual report on May 23, 2026.
Divi’s Laboratories Q4 Results: Net profit rises 13.4% YoY to Rs 751 crore, revenue up 9.5%
Divi's Laboratories reported a healthy set of earnings for the fourth quarter of FY26, supported by steady revenue growth and improved profitability on a year-on-year basis. The company also announced...
Top Q4 results today, May 23: NTPC, Divi's Laboratories, JK Cement, Reliance Infrastructure among key companies to announce earnings
More than 75 companies are scheduled to announce their Q4FY26 earnings on May 23, making it one of the busiest days of the ongoing earnings season. Key companies set to…
Pharma sector stocks today, March 12: Divi's Laboratories down 1.87%, Abbott India drops 1.51%, Aarti Drugs falls 1.36%
The Indian pharmaceutical sector experienced a decline on March 12, 2026, with most listed stocks trading lower in early morning sessions. The S&P BSE HEALTHCARE Index stood at 43,421.7, down…
M&M, Lenskart & more: Stocks to watch out for today
CLSA raised M&M's target price, expecting 20% EBITDA CAGR driven by strong utility vehicle leadership and a robust launch pipeline. HSBC initiated a buy on Hindalco, citing management's confidence in ...
Divi's Laboratories Transcript: Q3 25/26
Q3 FY26 saw strong revenue and profit growth, driven by custom synthesis and stable generics volumes, despite ongoing pricing pressures. Backward integration, capacity expansion, and a robust export mix supported performance, with major custom synthesis projects set for commercialization in late 2027.
Divi's Laboratories Quarterly report: Q3 2026
Divi's Laboratories has published its Q3 2026 quarterly earnings report on February 11, 2026.
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q3 2026 Earnings
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q3 2026 Earnings
Pharma sector stocks today, Feb 10: Pfizer rally 9%, GSK Pharma up 4.12%, Divis Laboratories rises 1.47%
The Indian pharmaceutical sector showed mixed performance on February 10, 2026, as of around 10:05 AM IST. The data provided...
Voltas, HCL Tech & more: Stocks to look out for today; check details
Nuvama downgraded Voltas citing weak near-term demand and high inventory, while Kotak sees improvement in SBI Cards' asset quality and spending. CLSA expects Dalmia Bharat's volumes to rise but margin...
Nykaa, Bajaj Auto & more: Top stocks on brokers' radar today
Analysts have downgraded Trent, citing weak consumption and competition, while Morgan Stanley maintains an overweight rating on Nykaa, impressed by its beauty and fashion business growth. Goldman Sach...
Divi's Laboratories Transcript: Q2 25/26
Q2 FY2026 saw 17% YoY revenue growth, record custom synthesis revenue, and stable generics volumes despite pricing pressure. CapEx will exceed INR 2,000 crore for FY2026, with major investments in capacity and technology. Gross margin remains stable at ~60% as product mix shifts toward custom synthesis.
Divi's Laboratories Quarterly report: Q2 2026
Divi's Laboratories has published its Q2 2026 quarterly earnings report on November 7, 2025.
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q2 2026 Earnings
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q2 2026 Earnings